{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T01:45:57Z","timestamp":1724723157345},"reference-count":53,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["bprch.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.beha.2016.08.027","type":"journal-article","created":{"date-parts":[[2016,11,5]],"date-time":"2016-11-05T07:15:48Z","timestamp":1478330148000},"page":"166-171","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["The role of stem-cell transplantation in the treatment of marginal zone lymphoma"],"prefix":"10.1016","volume":"30","author":[{"given":"Avichai","family":"Shimoni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2016.08.027_bib1","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissue","year":"2008"},{"key":"10.1016\/j.beha.2016.08.027_bib2","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1182\/asheducation.V2012.1.426.3798535","article-title":"The many faces of marginal zone lymphoma","author":"Zinzani","year":"2012","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.beha.2016.08.027_bib3","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1182\/blood-2015-12-624304","article-title":"The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance","volume":"127","author":"Zucca","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.027_bib4","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1182\/blood-2015-11-624312","article-title":"Splenic marginal zone lymphoma: from genetics to management","volume":"127","author":"Arcaini","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.027_bib5","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1182\/blood-2015-12-624296","article-title":"Optimizing therapy for nodal marginal zone lymphoma","volume":"127","author":"Thieblemont","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.027_bib6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.clml.2014.07.002","volume":"15","author":"Tarella","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.beha.2016.08.027_bib7","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/annonc\/mds643","article-title":"ESMO consensus conferences: guidelines on malignant lymphoma. Part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma","volume":"24","author":"Dreyling","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2016.08.027_bib8","series-title":"Non-Hodgkin's lymphomas","author":"NCCN Guidelines, version 1","year":"2014"},{"key":"10.1016\/j.beha.2016.08.027_bib9","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.blre.2012.09.004","article-title":"Management of indolent lymphoma: where are we now and where are we going","volume":"26","author":"Lunning","year":"2012","journal-title":"Blood Rev"},{"key":"10.1016\/j.beha.2016.08.027_bib10","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/10428190310001593157","article-title":"Autologous bone marrow transplantation for marginal zone non-Hodgkin's lymphoma","volume":"45","author":"Brown","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2016.08.027_bib11","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.clml.2011.03.011","article-title":"High-dose therapy\/autologous hematopoietic stem cell transplantation in relapsed or refractory marginal zone non-Hodgkin lymphoma","volume":"11","author":"Li","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.beha.2016.08.027_bib12","first-page":"124","article-title":"High dose therapy and autologous stem cell transplantation in marginal zone lymphoma: an EBMT-FIL-Gimeto retrospective study","author":"Avivi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.027_bib13","series-title":"Current uses and outcomes of hematopoietic stem cell transplantation","author":"Pasquini","year":"2015"},{"key":"10.1016\/j.beha.2016.08.027_bib14","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/sj.bmt.1702577","article-title":"Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (>\/=60 years) with non-Hodgkin's lymphoma: comparison with patients <60 years treated within the same protocol","volume":"26","author":"Jantunen","year":"2000","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.beha.2016.08.027_bib15","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood-2015-11-624320","article-title":"The role of autologous and allogeneic stem cell transplantation in the management of indolent B-cell lymphoma","volume":"127","author":"Kuruvilla","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.027_bib16","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/bmt.2012.182","article-title":"Reappraising the role of autologous transplantation for indolent B-cell lymphomas in the chemoimmunotherapy era: is it still relevant?","volume":"48","author":"Hamadani","year":"2013","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.beha.2016.08.027_bib17","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2016.08.027_bib18","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2016.08.027_bib19","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1182\/blood-2004-10-3920","article-title":"High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS","volume":"105","author":"Deconinck","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.027_bib20","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2004-03-0982","article-title":"Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group","volume":"104","author":"Lenz","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.027_bib21","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1182\/blood-2006-03-013193","volume":"108","author":"Sebban","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2016.08.027_bib22","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/jnci\/djr450","article-title":"Autologous stem cell transplantation in follicular lymphoma: a systematic review and meta-analysis","volume":"104","author":"Al Khabori","year":"2012","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.beha.2016.08.027_bib23","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1182\/blood-2007-10-116749","volume":"111","author":"Ladetto","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.027_bib24","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.3324\/haematol.2013.084723","article-title":"Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party","volume":"98","author":"Montoto","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2016.08.027_bib25","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","article-title":"High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial","volume":"21","author":"Schouten","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2016.08.027_bib26","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jnci\/djk152","article-title":"Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis","volume":"99","author":"Schulz","year":"2007","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.beha.2016.08.027_bib27","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.3324\/haematol.2010.030320","article-title":"Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA\/GOELAMS FL2000 study","volume":"96","author":"Le Gouill","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2016.08.027_bib28","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1200\/JCO.2007.15.5358","article-title":"Impact of rituximab and\/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study","volume":"26","author":"Sebban","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2016.08.027_bib29","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1038\/sj.leu.2404850","article-title":"Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study","volume":"21","author":"Montoto","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.08.027_bib30","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1200\/JCO.2006.09.8327","article-title":"Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up","volume":"25","author":"Rohatiner","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2016.08.027_bib31","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1093\/annonc\/mdu440","article-title":"The impact of total body irradiation on the outcome of patients with follicular lymphoma treated with autologous stem-cell transplantation in the modern era: a retrospective study of the EBMT Lymphoma Working Party","volume":"25","author":"El-Najjar","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2016.08.027_bib32","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1182\/blood-2003-04-1205","article-title":"Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma","volume":"102","author":"van Besien","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.027_bib33","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.bbmt.2007.11.004","article-title":"Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning","volume":"14","author":"Hari","year":"2008","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.beha.2016.08.027_bib34","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.1182\/blood-2012-03-417808","article-title":"Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results","volume":"119","author":"Khouri","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.027_bib35","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.3324\/haematol.2009.017608","article-title":"Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials","volume":"95","author":"Pi\u00f1ana","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2016.08.027_bib36","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.bbmt.2011.01.016","article-title":"Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901","volume":"17","author":"Shea","year":"2011","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.beha.2016.08.027_bib37","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.bbmt.2010.11.004","article-title":"Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response","volume":"17","author":"Tomblyn","year":"2011","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.beha.2016.08.027_bib38","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/bmt.2013.83","article-title":"The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT","volume":"48","author":"Robinson","year":"2013","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.beha.2016.08.027_bib39","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.bbmt.2015.07.028","article-title":"Reduced-intensity allografting as first transplantation approach in relapsed\/refractory grades one and two follicular lymphoma provides improved outcomes in long-term survivors","volume":"21","author":"Klyuchnikov","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.beha.2016.08.027_bib40","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2008.16.0283","article-title":"Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma","volume":"26","author":"Al-Tourah","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2016.08.027_bib41","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1136\/jcp.53.3.187","article-title":"Clinicopathological features of gastric mucosa associated lymphoid tissue (MALT) lymphomas: high grade transformation and comparison with diffuse large B cell lymphomas without MALT lymphoma features","volume":"53","author":"Yoshino","year":"2000","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.beha.2016.08.027_bib42","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/bjh.13320","article-title":"Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia","volume":"169","author":"Xing","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2016.08.027_bib43","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1182\/asheducation-2015.1.625","article-title":"Treatment of patients with transformed lymphoma","author":"Montoto","year":"2015","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.beha.2016.08.027_bib44","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1200\/JCO.2001.19.3.727","article-title":"High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry","volume":"19","author":"Williams","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2016.08.027_bib45","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1046\/j.1365-2141.2001.02705.x","article-title":"Autotransplants for histologically transformed follicular non-Hodgkin's lymphoma","volume":"113","author":"Chen","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2016.08.027_bib46","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.2012.44.0693","article-title":"Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group","volume":"31","author":"Villa","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2016.08.027_bib47","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.bbmt.2014.03.014","article-title":"Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma","volume":"20","author":"Wirk","year":"2014","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.beha.2016.08.027_bib48","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3109\/10428194.2011.631637","article-title":"High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era","volume":"53","author":"Ban-Hoefen","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2016.08.027_bib49","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/bjh.12570","article-title":"Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database","volume":"163","author":"Ban-Hoefen","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2016.08.027_bib50","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1093\/annonc\/mdt029","article-title":"Outcome of patients with transformed indolent non-Hodgkin lymphoma referred for autologous stem-cell transplantation","volume":"24","author":"Villa","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2016.08.027_bib51","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/bmt.2008.220","article-title":"Allogeneic SCT for relapsed composite and transformed lymphoma using related and unrelated donors: long-term results","volume":"42","author":"Ramadan","year":"2008","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.beha.2016.08.027_bib52","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1016\/j.bbmt.2014.07.015","article-title":"Favorable outcomes from allogeneic and autologous stem cell transplantation for patients with transformed nonfollicular indolent lymphoma","volume":"20","author":"Villa","year":"2014","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.beha.2016.08.027_bib53","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1600-0609.2008.01146.x","article-title":"High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma","volume":"81","author":"Hamadani","year":"2008","journal-title":"Eur J Haematol"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692616300809?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692616300809?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T04:30:13Z","timestamp":1601181013000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692616300809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":53,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S1521692616300809"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2016.08.027","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of stem-cell transplantation in the treatment of marginal zone lymphoma","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2016.08.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}